Navigation Links
UT Southwestern research advances fight against kidney cancer
Date:3/30/2011

DALLAS March 31, 2011 Researchers at UT Southwestern Medical Center have discovered genetic pathways to starve selectively kidney cancer cells.

Two separate studies indicate that both rare and common cases of kidney cancer may be susceptible to a new class of drugs that inhibits cancer cells from generating the energy needed to survive. In one study, available online and scheduled for the May 5 issue of the journal Oncogene, researchers found that inactivating the gene von Hippel-Lindau (VHL) in mice blocked cells from using oxygen to provide energy to the cell, forcing them to use another method of energy generation, such as glycolysis the conversion of glucose to lactic acid.

Because the VHL gene is inactive in about 90 percent of clear-cell renal cell carcinomas, the most common type of kidney cancer in humans, the study provides a rationale for the evaluation of glycolytic inhibitors in fighting kidney cancer, said Dr. James Brugarolas, assistant professor of internal medicine and developmental biology and the study's senior author.

"It would be expected to kill cancer cells preferentially and spare most normal cells that would still have mitochondrial respiration to rely on," said Dr. Brugarolas.

An estimated 58,000 new cases of kidney cancer were reported in the U.S. in 2010, and 13,040 died of the disease. Based on incidence of this cancer from 2005 to 2007, 1 in 67 people will be diagnosed with cancer of the kidney or renal pelvis during his or her lifetime.

The study also revealed that the effect of VHL loss was mediated by hypoxia-inducible factors (HIF), a family of proteins that binds to specific DNA sequences and responds to decreases in oxygen, known as hypoxia.

"We discovered that simultaneous inactivation of HIF rescued the mice from the effects of VHL inactivation," Dr. Brugarolas said. "To our knowledge, this is the first demonstration in a living organism that simply activating HIF is sufficient to block cells from using oxygen. It also indicates that there are no other pathways that can allow the use of available oxygen when HIF is active."

In a related study, Dr. Brugarolas examined the effectiveness of a specific glycolytic inhibitor, 2-deoxy-D-glucose (2DG), in treating a rare form of kidney cancer. The case study, available in the March 1 issue of Nature Reviews Urology, details efforts to develop a personalized treatment plan for a patient who presented with an uncommon kidney cancer type when she was 24. Without any familial predisposition for kidney or other cancers, the patient was found to have a mutation in a gene called fumarate hydratase, which has been found to be mutated in approximately 100 families worldwide and which confers a strong predisposition to kidney cancer. The mutation was a novel mutation, and the patient is likely to have been the founder, Dr. Brugarolas said.

The gene encodes an enzyme which is important for cells to be able to use oxygen and generate energy, and studies showed that the enzyme was completely inactive in the tumor. The patient, who had an advanced case of cancer, underwent surgery and then standard treatment with mTORC1 inhibitors. After five months, however, her tumor progressed and there were no other proven treatments available. Given this situation, Dr. Brugarolas looked for options to exploit what was known about the tumor. After a discussion with the UT Southwestern Institutional Review Board, the Food and Drug Administration and the drug manufacturer, Dr. Brugarolas managed to secure for his patient a drug in development, 2DG, which previously had been used only in clinical trials.

Because the tumor was deficient in fumarate hydratase, researchers speculated that 2DG would block glycolysis and kill tumor cells, as it had in the laboratory. The drug, however, failed to produce the same results for the patient, who later died. The patient had given permission to have her tumor studied and research continues; the tumor DNA has been sequenced and tumor samples have been implanted in mice.

"We have the tumor growing so that we can test new drugs that may emerge and hopefully help other patients with this rare cancer type," Dr. Brugarolas said. In addition, through analysis of all the mutated genes in the patient's tumor, "we may identify other mutations, which may give us clues about other approaches against this aggressive cancer type."

Efforts of the care team in the National Cancer Institute-designated Harold C. Simmons Cancer Center, "illustrate the type of discovery-based personalized cancer care we strive to provide at UT Southwestern," Dr. Brugarolas said.


'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
2. UT Southwestern researchers uncover Fragile X syndrome genes role in shaping brain
3. UT Southwestern participates in nationwide study offering free lung tumor genetic testing
4. Belly fat or hip fat -- it really is all in your genes, says UT Southwestern researcher
5. Novel anti-malarial drug candidate found by UT Southwestern researchers
6. Those with allergic asthma face double trouble during flu season, UT Southwestern findings suggest
7. UT Southwestern investigators perform head-to-head comparison of incontinence treatments
8. UT Southwestern unveils next generation CT scanner that views whole organs in a heartbeat
9. Simple eye test measures damage from multiple sclerosis, UT Southwestern researchers find
10. Interferon might help asthma patients breathe easier, UT Southwestern study suggests
11. UT Southwesterns cancer center earns National Cancer Institute designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... name the Creator responds to and which He does not. Yisrayl says with so ... one is the true name, but he says with a little Scripture, backed with a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. ... alliance with B. Braun Medical Inc. , a leader in infusion therapy and ... with as many as 90 percent of hospital patients receiving a peripheral IV catheter ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology: